Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>News>This Article

BASF, Cargill and Novozymes Achieve Milestone in Bio-Based Acrylic Acid Process

Published: Thursday, July 11, 2013
Last Updated: Thursday, July 11, 2013
Bookmark and Share
Success in producing 3-hydroxypropionic acid for bio-based acrylic acid.

BASF, Cargill and Novozymes have announced the achievement of an important milestone in their joint development of technologies to produce acrylic acid from renewable raw materials by successfully demonstrating the production of 3-hydroxypropionic acid (3-HP) in pilot scale.

3-HP is a renewable-based building block and one possible chemical precursor to acrylic acid. The companies also have successfully established several technologies to dehydrate 3-HP to acrylic acid at lab scale.

This step in the process is critical since it is the foundation for production of acrylic acid. In August 2012, BASF, Cargill and Novozymes announced their joint agreement to develop a process for the conversion of renewable raw materials into a 100 percent bio-based acrylic acid.

“3-HP is a potential key raw material for the production of bio-based acrylic acid which is a precursor of superabsorbent polymers,” said Teressa Szelest, Senior Vice President Global Hygiene Business at BASF.

Szelest continued, “We still have a fair amount of work to do before the process is commercially ready, but this is a significant milestone and we are confident we can continue to the next level of scale-up for the entire process in 2014.”

Acrylic acid is a high-volume chemical that feeds into a broad range of products. BASF is the world’s largest producer of acrylic acid and has substantial capabilities in its production and downstream processing.

BASF plans initially to use the bio-based acrylic acid to manufacture superabsorbent polymers that can soak up large amounts of liquid and are used mainly in baby diapers and other hygiene products.

Presently, acrylic acid is produced by the oxidation of propylene derived from the refining of crude oil.

The companies’ joint project team combines world-class expertise in biotechnology, renewable feedstock, industrial scale fermentation, and in developing new chemical processes.

“Our three companies have assembled highly talented and experienced joint working teams for this project,” said Jack Staloch, Vice President of Biotechnology R&D at Cargill.

Staloch continued, “They’ve moved with speed and intensity, and have demonstrated great progress toward accomplishing our goals.”

“We have reached an important milestone by producing 3-HP in pilot scale,” said Rasmus von Gottberg, Vice President of Corporate Development and Business Creation at Novozymes. “We have shown that it is possible to make this key chemical building block from renewable raw materials in robust industrial conditions. Now the development work will continue towards commercialization.”

Superabsorbent polymers derived from bio-based acrylic acid will be a groundbreaking new offer to the market. Diapers made of such superabsorbent polymers could meet the demand of a significant and growing group of consumers in mature markets in particular.

They also may allow diaper producers to meet consumer demands, differentiate their products and contribute to their sustainability goals.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Novozymes Biopharma Helps Innovative Dry Eye Therapy Move into Clinical Trials
A novel ophthalmic solution has recently obtained FDA approval to undergo Phase I/II clinical trials in the United States.
Monday, May 20, 2013
Scientific News
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
Antibody Treatment Efficacious in Psoriasis
An experimental, biologic treatment, brodalumab, achieved 100 percent reduction in psoriasis symptoms in twice as many patients as a second, commonly used treatment, according to the results of a multicenter clinical trial led by Mount Sinai researchers.
Scientists Test New Gene Therapy for Vision Loss from a Mitochondrial Disease
NIH-funded study shows success in targeting mitochondrial DNA in mice.
HIV Patients Should Be Included in Early Clinical Trials of Anti-TB Drugs
Tuberculosis is the number one cause of death in HIV-infected patients in Africa and a leading cause of death in this population worldwide.
Multi-Gene Test Enables Some Breast Cancer Patients to Safely Avoid Chemotherapy
A major study is providing the best evidence to date that a 21-gene test done on the tumor can identify breast cancer patients who can safely avoid chemotherapy.
Low Dose Beta-Blockers As Effective As High Dose After a Heart Attack?
Heart attack patients live as long – or even longer – on one-quarter the suggested dose.
Antidepressants Plus Blood-Thinners Slow Down Brain Cancer
EPFL scientists have found that combining antidepressants with anticoagulants slows down brain tumors (gliomas) in mice.
Old Drug Performs New Tricks
Cambridge-led research reveals the powers of a "wonder drug" that has lain under the noses of doctors for 50 years.
Electronic Reminders Keep TB Patients on Track With Medication In China
Giving electronic reminders to tuberculosis (TB) patients in China can reduce the amount of medication doses they miss by half, according to new research.
Scroll Up
Scroll Down

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos